|
Tobacco Centers of Regulatory Science (TCORS)
|
Research Initiative
|
FDA
|
OD/DPCPSI/ODP
|
The Tobacco Regulatory Science Program located in the National Institutes of Health (NIH) Office of Disease Prevention coordinates the trans-NIH collaboration effort with the Food and Drug Administration (FDA) Center for Tobacco Products to conduct research that is needed to ensure that US tobacco regulatory actions and activities are based on sound and relevant scientific evidence. The U54 Tobacco Centers of Regulatory Science (TCORS) are the centerpiece of this NIH-FDA collaboration. The TCORS are expected to demonstrate research excellence and leadership in tobacco regulatory science that will contribute to the science base that FDA will use to develop meaningful product regulation, which will, in turn, reduce the toll of tobacco-related disease, disability, and death in the United States. Essential elements of the TCORS include at least three theoretically grounded, strong research projects with an integrative theme; an Administrative Core and other cores as needed; the ability to conduct developmental/pilot and time-sensitive research; and a program for career development. Nine TCORS, made up of scientists with a broad range of expertise (e.g., epidemiology, economics, toxicology, addictions, and marketing) are currently funded.
|
|
Tobacco Product Disease Risks
|
Research Initiative
|
FDA
|
NCI
|
The National Cancer Institute (NCI) and the Food and Drug Administration (FDA) Center for Tobacco Products, in collaboration with the US Census Bureau, co-lead this study, which harmonizes data on cigarette, cigar, and pipe use from various Tobacco Use Supplements that have been administered over the years as part of the Current Population Survey. The participants in these surveys have been followed for mortality by linkage to the National Death Index. These data are used to provide contemporary estimates of the mortality risks of daily and non-daily use of cigarettes, pipes, and cigars.
|
|
Tobacco Products Scientific Advisory Committee (TPSAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, SAMHSA
|
OD/DPCPSI/ODP
|
TPSAC advises the Food and Drug Administration (FDA) Commissioner or designee in discharging responsibilities as they relate to the regulation of tobacco products. The Committee reviews and evaluates safety, dependence, and health issues relating to tobacco products and provides appropriate advice, information and recommendations to the Commissioner of Food and Drugs.
|
|
Tobacco Regulatory Science Program (TRSP)
|
Research Initiative
|
FDA
|
OD/DPCPSI/ODP, CSR, NCI, NHLBI, NIAAA, NICHD, NIDA, NIEHS, OD/OER
|
Located in the National Institutes of Health (NIH) Office of Disease Prevention, the Tobacco Regulatory Science Program (TRSP) coordinates the trans-NIH collaborative effort with the US Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) to conduct research to support its regulatory activities over tobacco products. Within the framework of the Tobacco Control Act, the NIH and FDA formed an interagency partnership to foster tobacco regulatory research. The NIH has the infrastructure for the solicitation, review, and management of research. The FDA has expertise in tobacco regulatory science and the authority and resources to support research responsive to FDA’s regulatory authority. Support from FDA was used to fund grants and to provide administrative support and oversight to manage Funding Opportunity Announcements (FOA), application review, policy implementation and oversight, and communicating and reporting to a variety of sources.
|
|
Tobacco Use Supplement to Current Population Survey
|
Health Survey
|
CDC, FDA
|
NCI, NIMHD
|
The Tobacco Use Supplement to the Current Population Survey (TUS-CPS) is an National Cancer Institute (NCI)-sponsored survey of tobacco use that has been administered as part of the US Census Bureau''s Current Population Survey approximately every 3-4 years since 1992-93.
|
|
Tox 21
|
Resource Development
|
FDA
|
NCATS, NIEHS
|
The Toxicology in the 21st Century (Tox21) program is a federal collaboration among National Institutes of Health (NIH) National Center for Advancing Translational Science (NCATS) and the National Toxicology Program at the National Institute of Environmental Health Sciences; the Environmental Protection Agency; and the Food and Drug Administration. Tox21 researchers aim to develop better toxicity assessment methods to quickly and efficiently test whether certain chemical compounds have the potential to disrupt processes in the human body that may lead to negative health effects.
|
|
Toxin Working Group of the Intragovernmental Select Agents and Toxins Technical Advisory Committee (ISATTAC)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIAID
|
The workgroup holds biweekly meetings to discuss the following: point of regulation of select toxins (Botulinum neurotoxins, Staphylococcal enterotoxins, Abrin, Ricin, Conotoxins, Saxitoxin, Tetrodotoxin, Diacetoxyscirpenol, T-2 toxin), natural environment, toxin exclusion limits, space decontamination, and potential updates to the Centers for Disease Control and Prevention (CDC) manual “Biosafety in Microbiological and Biomedical Laboratories.”
|
|
Training on Implementing Collaborative Care Model for Behavioral Health Conditions in Nurse-Led Safety-Net Clinics.
|
Training Initiative
|
HRSA
|
NIMH
|
The National Institute of Mental Health (NIMH) and the Health Resources and Services Administration (HRSA) are partnering on an initiative to implement a Collaborative Care model in nurse-led safety net clinics supported by HRSA. NIMH is supporting this initiative via a contract to provide training to the HRSA-funded Nurse Education, Practice, Quality and Retention- Interprofessional Collaborative Practice Program: Behavioral Health Integration (NEPQR-IPCP: BHI) awardees who choose to take part in this initiative. Training will be aimed at ensuring awardees implement the IMPACT Collaborative Model of Depression Care with fidelity. The training will be composed of two phases. Phase 1 aims to establish and deliver an initial training program for successful implementation of collaborative care. Phase 2 aims to provide follow up training and implementation support after the in-person training to ensure fidelity of collaborative care delivery.
|
|
Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR)
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
The presidential declaration issued at the 2009 EU-US summit called for the creation of “a transatlantic task force on urgent antimicrobial resistance issues focused on appropriate therapeutic use of antimicrobial drugs in the medical and veterinary communities, prevention of both healthcare- and community-associated drug-resistant infections, and strategies for improving the pipeline of new antimicrobial drugs, which could be better addressed by intensified cooperation between us.” The objectives of the Trans-Atlantic Task Force on Antimicrobial Resistance (TATFAR) are to increase the mutual understanding of US and EU activities and programs relevant to the antimicrobial resistance issues identified in the declaration in order to deepen the transatlantic dialogue, provide opportunities to learn from each other, and promote information exchange, coordination, and cooperation.
|
|
Trans-National Institutes of Health (NIH) Tuberculosis (TB) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, FIC, NCATS, NCI, NHLBI, NIAAA, NIAID, NIDA, NIGMS, OD/DPCPSI/OAR
|
The TB Working Group provides a forum for sharing information about NIH-specific TB projects, including both ongoing and proposed research, including extramural funding initiatives. In addition, the working group fosters continual open communication about TB research being conducted across NIH and maintains a consistent message about the importance of NIH intramural and extramural TB research. It also provides an avenue for the introduction of new technology programs of interest and importance for TB research (such as the "human on a chip"). The working group invites guests/speakers from outside NIH and convenes invitations for teleconference participation to other US Government agencies including the Centers for Disease Control and Prevention (CDC) and the US Agency for International Development (USAID).
|